



# Site of Service Program

As a part of our mission to provide access to quality and affordable care for our members, Blue Shield of California may direct members with prescriptions for medication infusion therapy services in an outpatient setting to receive care provided by qualified non-hospital-owned infusion centers or physician offices.\* Our medical policy also allows an eligible member to receive medication infusion therapy at their personal physician’s office, or in their own home when administered by a licensed and qualified clinician.

Guiding a member to receive this care in a way that best addresses their individual needs may reduce their out-of-pocket cost<sup>±</sup> and travel time. If you have any questions about Blue Shield’s Site of Service Program, contact our Provider Customer Service team via Live Chat after logging into Provider Connection at [www.blueshieldca.com/provider](http://www.blueshieldca.com/provider) or by telephone at (800) 541-6652, Monday through Friday, 6 a.m. to 6:30 p.m.

Drugs included in the Blue Shield Site of Service Program as of August 2023

HCPCS	Generic / Brand
90291	IVIG (Cytogam per dose)
J0850	IVIG (Cytogam® per 50 ml vial)
J1459	IVIG (Privigen)
J1554	IVIG (Asceniv)
J1556	IVIG (Bivigam)
J1557	IVIG (Gammaplex)
J1561	IVIG or SCIG (Gamunex-C or Gammaked)
J1566	IVIG (Lyophilized (powder), not otherwise specified, (Gammagard S/D))
J1568	IVIG (Octagam)
J1572	IVIG (Flebogamma)
J1576	IVIG (Panzyga - effective 7/1/23 & after)
J1599	IVIG (Panzyga - effective 4/1/23 to 6/30/23)
J1569	IVIG or SCIG (Gammagard S/D)
J1551	SCIG (Cutaquig)
J1555	SCIG (Cuvitru)
J1558	SCIG (Xembify)
J1559	SCIG (Hizentra)
J1575	SCIG (Hyqvia)
J0791	Crizanlizumab-tmca (Adakveo)
J3262	Toclizumab (Actemra)
J1426	Casimersen (Amondys 45)
J0225	Vutrisiran (Amvuttra)
Q5121	Infliximab-Axxq (Avsola)
J0490	Belimumab (Benlysta)
J2329	Ublituximab-Xiiy (Briumvi)
J1786	Imiglucerase Inj (Cerezyme)
J2786	Reslizumab (Cinqair)
J0598	C-1 Esterase (Cinryze)
J0584	Burosumab-Twza (Crysvita)
J1743	Idursulfase (Elaprase)
J3060	Taliglucerase Alfa (Elelyso)
J3590	Pegunigalsidase alfa-iwxj (Elfabrio)
J1302	Sutimlimab-Jome (Enjaymo)
J3380	Vedolizumab (Entyvio)
J3111	Romosozumab-Aqqg (Evenity)
J1305	Evinacumab-Dgnb (Evkeeza)
J1428	Eteplirsen (Exondys 51)
J0180	Agalsidase Beta (Fabrazyme)

J0517	Benralizumab (Fasenra)
J0223	Givosiran (Givlaari)
J0638	Canakinumab (Ilaris)
J3245	Tildrakizumab-Asmn (Ilumya)
Q5103	Infliximab-Dyyb (Inflectra)
J2840	Sebelipase Alfa (Kanuma)
J0202	Alemtuzumab (Lemtrada)
J1306	Inclisiran (Leqvio)
J0221	Alglucosidase Alfa (Lumizyme)
J1729	Hydroxyprogesterone Caproate (Makena)
J3397	Vestronidase Alfa-Vjbc (Mepsevii)
J1458	Galsulfase (Naglazyme)
J0219	Avalglucosidase Alfa-Ngpt (Nexviazyme)
J2182	Mepolizumab (Nucala)
J2350	Ocrelizumab (Ocrevus)
J0222	Patisiran (Onpattro)
J0129	Abatacept (Orencia)
J0224	Lumosiran (Oxlumo)
J1576	Letermovir (Prevymis)
J1301	Edaravone (Radicava)
J1745	Infliximab (Remicade)
Q5104	Infliximab-Abda (Renflexis)
J2998	Plasminogen, Human-Tvmh (Ryplazim)
J0491	Anifrolumab-Fnia (Saphnelo)
J1602	Golimumab (Simponi Aria)
J2327	Risankizumab-Rzaa (Skyrizi)
J1300	Eculizumab (Soliris)
J3357	Ustekinumab (Stelara)
90378	Palivizumab (Synagis)
J3241	Teprotumumab-Trbw (Tepezza)
J2356	Tezepelumab-Ekko (Tezspire)
J1746	Ibalizumab-Uiyk (Trogarzo)
J2323	Natalizumab (Tysabri)
J1303	Ravulizumab-Cwvz (Ultomiris)
J1823	Inebilizumab-cdon (Uplizna)
J1427	Viltepso (Viltolarsen)
J1322	Elosulfase Alfa (Vimizim)
J3385	Velaglucerase Alfa (VPRIV)
J3032	Eptinezumab-Jjmr (Vyepiti)
J1429	Golodirsen (Vyondys 53)
J9332	Efgartigimod Alfa-Fcab (Vyvgart)
J0218	Olipudase Alpha-Rpcp (Xenpozyme)
J2357	Omalizumab (Xolair)

\*Authorization requests for medication infusion therapy and its administration at an outpatient hospital facility will require clinical rationale and documentation for medical necessity of the site of care. If medical necessity criteria are not met for outpatient hospital facility infusion, payment may be delayed or denied. ±Most medical benefits require members to pay a percentage of the bill. ±Most medical benefits require members to pay a percentage of the bill.